CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $4.89B, above the global median of $1.15B
- FinancialsAltman Z-Score 9.19: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.79%Below 5Y avg (2.96%)
Annual Rate
CNY 1.44Paid annual
Payout Ratio
92.6%High
Payback Period
33.7 yr
Last Ex-Dividend
May 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
32.94BCNY4.89B · vs all stocks (USD)
Trailing P/E
18.73xRevenue (TTM)
6.80BCNY1.01B · vs all stocks (USD)
Profit Margin
26.03%Beta
0.0330xvs all stocks
52-Week Change
1.34%vs all stocks
Market Capitalization
32.94BCNY4.89B · vs all stocks (USD)
Enterprise Value
24.06BCNY3.57B · vs all stocks (USD)
Trailing P/E
18.73xForward P/E
14.80xPEG Ratio
2.66xPrice to Sales (TTM)
4.85xPrice to Book (MRQ)
3.07xEnterprise to Revenue
3.54xEnterprise to EBITDA
11.16xGross Margin
75.52%Profit Margin
26.03%Operating Margin
28.53%Return on Assets (TTM)
9.47%Return on Equity (TTM)
16.38%Revenue (TTM)
6.80BCNY1.01B · vs all stocks (USD)
Revenue per Share (TTM)
10.55CNYUpdated Aug 18, 2026Quarterly Revenue Growth
5.50%Gross Profit (TTM)
5.02BCNY744.74M · vs all stocks (USD)
EBITDA (TTM)
2.22BCNY328.73M · vs all stocks (USD)
Net Income (TTM)
1.77BCNY262.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.10%Operating Cash Flow (TTM)
2.62BCNY388.43M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.18BCNY322.78M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.44CNYUpdated Aug 18, 2026Trailing Annual Dividend Yield
2.79%vs all stocks
5-Year Average Dividend Yield
2.96%vs all stocks
Payout Ratio
92.57%Minority Interest (Equity)
26.93MCNYFY2025 · Dec 31, 2025Revenue
6.70BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.78BCNYFY2025 · Dec 31, 2025Gross Profit
4.92BCNYFY2025 · Dec 31, 2025Operating Income
1.97BCNY291.56M · vs all stocks (USD)
Pre-tax Income
2.06BCNYFY2025 · Dec 31, 2025Income Tax Expense
321.27MCNYFY2025 · Dec 31, 2025Net Income
1.74BCNYFY2025 · Dec 31, 2025EBIT
2.07BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.22BCNYFY2025 · Dec 31, 2025Research & Development
272.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.84BCNYFY2025 · Dec 31, 2025Other Operating Expenses
90.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
58.87MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.59MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.70CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.70CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
643.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
643.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.74BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
68.88KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.03BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.96BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.41BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.74BCNYFY2025 · Dec 31, 2025Other Non-cash Items
-30.74MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
253.28MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
66.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
-67.04MCNYFY2025 · Dec 31, 2025Net Acquisitions
-95.86MCNYFY2025 · Dec 31, 2025Purchase of Investments
-11.60BCNYFY2025 · Dec 31, 2025Sale of Investments
11.83BCNYFY2025 · Dec 31, 2025Other Investing Activity
36.84MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
105.72MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00CNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.64BCNYFY2025 · Dec 31, 2025Other Financing Charges
-81.93MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.72BCNYFY2025 · Dec 31, 2025Shares Outstanding
643.98MSharesUpdated Aug 18, 2026Float Shares
423.94MSharesUpdated Aug 18, 2026% Held by Insiders
36.95%vs all stocks
% Held by Institutions
10.93%vs all stocks
Total Cash (MRQ)
9.13BCNY1.35B · vs all stocks (USD)
Total Cash per Share (MRQ)
14.21CNYUpdated Aug 18, 2026Total Debt (MRQ)
64.98MCNY9.64M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0060xCurrent Ratio (MRQ)
4.20xBook Value per Share (MRQ)
16.80CNYUpdated Aug 18, 2026Total Assets
13.38BCNY1.98B · vs all stocks (USD)
Total Current Assets
10.55BCNYFY2025 · Dec 31, 2025Total Liabilities
3.02BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.83BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
158.58MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.86BCNYFY2025 · Dec 31, 2025Cash
5.19BCNYFY2025 · Dec 31, 2025Cash Equivalents
73.37MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
5.27BCNYFY2025 · Dec 31, 2025Other Short-term Investments
3.82BCNYFY2025 · Dec 31, 2025Accounts Receivable
132.24MCNYFY2025 · Dec 31, 2025Inventory
835.54MCNYFY2025 · Dec 31, 2025Accounts Payable
372.33MCNYFY2025 · Dec 31, 2025Short-term Debt
20.79MCNYFY2025 · Dec 31, 2025Other Current Liabilities
64.49MCNYFY2025 · Dec 31, 2025Long-term Debt
38.63MCNYFY2025 · Dec 31, 2025Common Stock (Book)
643.98MCNYFY2025 · Dec 31, 2025Retained Earnings
8.99BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
10.36BCNY1.54B · vs all stocks (USD)
Treasury Stock
142.24MCNYFY2025 · Dec 31, 202552-Week Low
42.88CNYUpdated Aug 18, 202652-Week High
58.36CNYUpdated Aug 18, 202652-Week Change
1.34%vs all stocks
Beta
0.0330xvs all stocks
50-Day MA
49.72CNYUpdated Aug 18, 2026200-Day MA
51.16CNYUpdated Aug 18, 2026Avg 10-Day Volume
5.75MSharesUpdated Aug 18, 2026Avg 30-Day Volume
6.47MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
2.75CNYUpdated Aug 18, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.19: safe zoneNotable
Altman Z-Score: 9.19
High structural barrier to entryNotable
Barrier to Entry: 0.55
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $4.89B, above the global median of $1.15BNotable
Market cap (USD): 4,885,696,513.666Global Median: 1,146,734,693.424
Revenue is $1.01B, above the global median of $520.53MNotable
Revenue (USD): 1,007,754,583.501Global Median: 520,528,949.311
Levered free cash flow is $322.78M, above the global median of $16.24MNotable
Levered free cash flow (USD): 322,779,463.066Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Sk Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Changchun High-Tech Industry Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ajanta Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ipca Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Deckers Outdoor Corporation
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
DPM Metals Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth
Alphabet Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksMulti-Year Revenue, Profit, And Income Growth